Jim Cramer: Short Sellers Are Coming Up Short

Much of Tuesday's rally is on the backs of hedge funds who -- poorly positioned for the Wuhan coronavirus -- started shorting virus-related stocks right into Friday.

Taking Stock of the Coronavirus Threat

How bad could this get and how should investors should respond? Let's take a step back to find out.

Gilead Sciences Coronavirus Treatment News Could Lead to Key Upside Breakout

Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.

Don't Underestimate Vertex Pharmaceuticals

Here's how the stock might surprise Wall Street.

WARS Hits 'Red Alert' Status and Surpasses SARS

The Wuhan coronavirus has now infected more people than SARS ever did. The WHO's designation of a global public-health 'concern' helps, but China finds itself increasingly isolated.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

Hologic's Charts and New Quant Rating Make It an Attractive Long Idea

Let's see if the two are in alignment.

Stryker Shares Could Continue to Struggle in the Weeks Ahead

The stock of the medical device maker has been stagnant for months and its charts have yet to prove themselves.

Thermo Fisher Scientific Could Trade Higher in the Weeks and Months Ahead

The charts of TMO are positive.

Line Up This Trade With Align Technology

Here's how to play ALGN, which is expected to report later Wednesday, three weeks from its Feb. 21 expiration.